Investment Proposition

Disruptive Diagnostic Innovation

The iKOr™ microcatheter system delivers complete coronary physiology, offering more accurate diagnostics for complex heart conditions, especially ANOCA which affects 5x more women.

  • Fiber-optic technology provides real-time, precise measurements, empowering cardiologists to make data-driven treatment decisions.
  • The iKOr™ system uniquely integrates all diagnostic methods in one device, enhancing efficiency and accuracy.

Significant Market Opportunity:

  • Addressing a potential $2B+ market in coronary diagnostics, with 9% CAGR, driven by unmet needs in diagnosing microvascular disease.
  • Re-imbursement in place in US.

Strong Clinical and Regulatory Momentum:

  • Successful First-in-Human trials at Barts, London, demonstrating safety and efficacy.
  • Improved diagnostics would enable clinicians to stratify patients accurately, guiding more personalized and effective treatment plans.
  • FDA 510(k) pathway confirmed with market clearance expected in Q1 2026, strategically positioning for US market entry.

High-Value Exit Potential:

  • Attractive M&A opportunities with recent acquisitions in cardiovascular diagnostics ranging from $100M to $13B.
  • Led by a seasoned executive team with proven track records in MedTech commercialization and strategic exit.

“With FDA clearance expected in early 2026 and reimbursement pathways already confirmed, the US market represents a $2B+ opportunity for our innovative platform. Backed by a successful First-in-Human study and led by a seasoned team—including women’s health advocate Nancy Briefs—we are uniquely positioned to transform the standard of care.”

“I’d welcome the chance to discuss how you can join us in reshaping women’s heart health.”

Antony Odell CEO